Skip to content
Contact
Dew-covered hemp plant on the right against a soft, light blurred background

CanSoul Fund – Cannabis Equity UCITS ETF

Europe's first hemp & cannabis ETF

CanSoul identifies promising listed hemp and cannabis companies worldwide and opens up access to this market for private and institutional investors.

Europe's first ETF for hemp and cannabis – global, exchange-traded, actively managed.

The ETF Sales documents (opens an external website)
WKN
A2PX8U
ISIN
LI0514446843

Positioning

One ETF for the entire value chain of the cannabis industry

The ETF identifies promising listed hemp and cannabis companies worldwide and invests up to 100% in leading cannabis stocks, initially predominantly in North America.

The investment processes are continuously refined in dialogue with industry experts. The sector is highly volatile; the strategy is long-term.

About CanSoul

Value chain covered

  • Cultivation
  • Patents and licences
  • Research
  • Development
  • Technology
  • Extraction
  • Software
  • Distribution
  • Product range
  • Infrastructure
  • CBD
  • Adult use
  • Medicine
  • Pharmaceuticals

The ETF in figures

Key facts

Source: IFM Independent Fund Management AG; portfolio according to the CanInsight profile.

  • 28

    companies in the portfolio from the USA and Canada (as of 28 Aug 2026)

  • 14

    industry segments of the hemp economy considered

  • €10.5million

    ETF assets (as of 5 Nov 2026)

  • €3.45

    unit price of share class EUR-S (as of 5 Nov 2026)

The currently valid sales documents are the sole basis for purchasing units. Past performance is not a reliable indicator of future results.

Three themes

Where the cannabis plant moves markets

Value chain

From cultivation to the stock exchange

CanSoul looks at the hemp and cannabis industry along its entire value chain – from cultivation through extraction and product to distribution and the capital market.

The portfolio includes licensed producers, multi-state and multi-country operators, REITs, equipment suppliers, pharmaceutical, extraction, CBD, food & drink and software companies.

  1. 01 Cultivation
  2. 02 Extraction
  3. 03 Product
  4. 04 Distribution
  5. 05 Stock exchange
  1. A hand gently touches the leaves of a young cannabis plant in a field

    Stage 01 of 05

    Cultivation

    Licensed producers (Canada) and multi-state operators (USA) grow the plant – in greenhouses, outdoors and indoors. Equipment suppliers and REITs provide technology and land.

  2. Amber-coloured cannabis extract stretching from a metal tool

    Stage 02 of 05

    Extraction

    Flowers and biomass are turned into extracts, isolates and active ingredients – the basis for THC & CBD products, pharmaceuticals and cannabis 2.0.

  3. Two dried cannabis flowers on a white surface

    Stage 03 of 05

    Product

    Flowers, oils, edibles, beverages, cosmetics, superfood, building materials and much more: the product range spans from adult use to industry.

  4. Five identical amber apothecary jars holding dried hemp flower, lined up on an oak shelf against a deep green wall

    Stage 04 of 05

    Distribution

    Licensed sale to adults in legalised jurisdictions, pharmacies, specialist retail and online – supported by compliance, software and infrastructure.

  5. Column chart of around forty narrow green bars on a fine baseline, rising from left to right against a pale paper background

    Stage 05 of 05

    Stock exchange

    CanSoul bundles selected listed cannabis stocks from this value chain in a UCITS ETF, giving private and institutional investors access to the market.

A wide hemp field under a cloudy sky, the plants glowing in warm evening light

Market overview

A market being reshaped by regulation

  • Since 28 April 2026 the US Drug Enforcement Administration lists medical cannabis from state-licensed programmes and FDA-approved cannabis products in Schedule III. Licensed medical operators are therefore no longer subject to Section 280E of the US tax code. A decision on full rescheduling will be made after the hearing held in summer 2026.
    • 24 US states and Washington, D.C. allow adult use of cannabis; 41 states allow medical use.
    • Germany legalised possession and home cultivation for adults on 1 April 2024. Imports of medical cannabis rose to 201 tonnes in 2025, almost three times the previous year.
    • In April 2026 Canadian producer Organigram acquired Berlin-based Sanity Group for up to 250 million euros, the largest acquisition in the German market to date.

  • $29.1 bn

    legal cannabis sales in the USA in 2025 (Whitney Economics)

  • C$5.6 bn

    Canadian cannabis retail sales in 2025 (Statistics Canada)

  • 201 t

    medical cannabis imported into Germany in 2025 (BfArM)

  • $14.5 bn

    market capitalisation of listed cannabis companies, September 2026

Partners

Financial and cooperation partners

Financial partners

Cooperation partners